Bayer HealthCare - FDA Approves Xarelto® (rivaroxaban tablets) for the Prophylaxis of Deep Vein Thrombosis Which May Lead to a Pulmonary Embolism in Patients Undergoing Knee or Hip Replacement Surgery
Links shared publicly online about this topic.
- 173total visits
Bayer HealthCare - FDA Approves Xarelto® (rivaroxaban tablets) for the Prophylaxis of Deep Vein Thrombosis Which May Lead to a Pulmonary Embolism in Patients Undergoing Knee or Hip Replacement Surgery
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. The company combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Diabetes Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality
View full resource at press.bayerhealthcare.com
Tags: Circulation, Thrombotic Event, Healthcare, FDA, Anti-Clotting Medication, Xarelto, Bayer
Most Recently Shared on July 3, 2011 at 6:25 pm By:
FDA Approves Xarelto® for the Prophylaxis of Deep Vein Thrombosis ......... http://t.co/yn1AQsl
Advertisement
